A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

D'Angelo, SP; Hamid, OA; Tarhini, A; Schadendorf, D; Chmielowski, B; Collichio, FA; Pavlick, AC; Lewis, KD; Weil, SC; Heyburn, J; Schweizer, C; O'Shannessy, DJ; Carvajal, RD

Carvajal, RD (reprint author), Columbia Univ, Med Ctr, 177 Ft Washington Ave, New York, NY 10032 USA.

INVESTIGATIONAL NEW DRUGS, 2018; 36 (1): 103

Abstract

Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor strom......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索